Use a step stool or a thick book(s)
AbbVie Bayer AG Teva Pharmaceutical Industries Ltd
Manufacturer savings cards (Novo Nordisk and Lilly both offer programs), insurance coverage, the oral Wegovy tablet, and patient assistance programs
placebo 14%)
Subgroup analyses revealed important differences based on comparator drugs: GLP-1RAs demonstrated greater effectiveness than SGLT2 inhibitors in preventing MALOs (IRR: 0.93, 95%CI: 0.87-0.99, P = 0.043), than DPP-4 inhibitors in preventing hepatic decompensation events (IRR: 0.74, 95%CI: 0.66-0.83, P = 0.003), and than insulin therapy in averting HCC development (IRR: 0.32, 95%CI: 0.13-0.80, P = 0.033) [64]
Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, Kushner R, Rubino DM, Zeuthen N, Verma S